13 completed. 13 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 1 | Completed 1 |
Follow PROSTVAC: new trials by email Literature Review of PROSTVAC trials Research Report on PROSTVAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824) - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2018-03-20 | 2025-06-19 |
| Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer PROSTVAC-V, PROSTVAC-F, Docetaxel - Prostate Cancer, Prostate Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2016-01-19 | 2026-04-29 |
| Prostvac in Patients With Biochemically Recurrent Prostate Cancer PROSTVAC -V, PROSTVAC-F - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 97 | 2015-12-22 | 2022-11-14 |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 154 | 2015-06-03 | 2023-07-19 |
| Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 57 | 2013-08-12 | 2023-09-26 |
| Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi) - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 38 | 2013-07-22 | 2020-09-16 |
| Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2007-02-23 | 2018-11-29 |
| A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine - Recurrent Prostate Carcinoma, Stage I Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2006-02-01 | 2015-06-30 |
| Sequential Vaccinations in Prostate Cancer Patients Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM) - Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2003-05-22 | 2017-10-26 |
| Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2002-08-01 | 2013-06-19 | |
| PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer rV-PSA, rF-PSA, rV-B7.1 - Prostate Cancer, Prostate Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2000-06-13 | 2017-07-02 |
| Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-06-01 | 2015-04-29 | |
| PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine - Prostate Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 60 | 1999-09-24 | 2023-06-22 |
Prostatic Neoplasms (12)
National Cancer Institute (NCI) (12) · Eastern Cooperative Oncology Group (1)
United States (13)
Ravi A Madan, M.D. (5) · Philip M. Arlen, MD (2) · Howard L. Kaufman, MD (1) · James L Gulley, M.D. (1) · John K Parsons (1) · Melissa Abel, M.D. (1) · Robert DiPaola (1)
PMID 15169798, PMID 16006888, PMID 16489082, PMID 17707059, PMID 18628467, PMID 22932804, PMID 30197041, PMID 33664086, PMID 37134294
N01CN00031 (1), P30CA023074 (1), U10CA021115 (1)